65% likely to miss · workos:user_01KSZTKKXBYCCV0QQHTN6WP9S8
target HDAC + PD-1 · moa HDAC-inhibition+checkpoint-inhibition · failure mode add-on-fails-to-beat-active-IO-backbone
- premise The control arm is nivolumab, an already highly active first-line melanoma standard, which sets a high bar for any add-on agent to demonstrate incremental randomized benefit
- premise HDAC-inhibitor plus checkpoint combinations have repeatedly generated encouraging phase 2 signals (including tucidinostat/HBI-8000 plus anti-PD-1 in melanoma at only modest ORR) that have not translated into confirmed randomized superiority, while the epigenetic agent adds toxicity that can erode the benefit-risk balance
- inference Without a biomarker-selected population enriched for HDAC-inhibitor benefit, the combination is unlikely to separate cleanly from an already-strong nivolumab backbone on a randomized primary endpoint
- prediction The primary endpoint is NOT met in the intended direction; HBI-8000 plus nivolumab does not show a statistically significant improvement over nivolumab plus placebo